GL1X · GenesisL1 explorer

MolNFT v1 · #27487 · protein

Crystal structure of mouse carnitine octanoyltransferase

1XL7 · Peroxisomal carnitine O-octanoyltransferase: “Crystal structure of mouse carnitine octanoyltransferase”. X-ray diffraction, 8 pockets (best druggability 0.79). MolNFT v1 #27487 on GenesisL1: 3D structure, binding sites and pockets…

PDB
1XL7
Type
protein
Length
1,191 residues
Chains
2
Method
x-ray diffraction
Collection
MolNFT v1 / PDB
Contract
0xDE3723766Bc32dcACD03C17BaA400A7B36837Eba
Owner
0x3396CDB397284571d12822B4ae1189a8E22AAAAA
Molecule
Peroxisomal carnitine O-octanoyltransferase
EC
2.3.1.137
UniProt
Q9DC50
Pockets
8 · best druggability 0.79

Structure

x-ray diffraction · 2 distinct chains · 48% helix, 15% strand (DSSP).

ChainMoleculeTypeResiduesSecondary structureUniProt
APeroxisomal carnitine O-octanoyltransferase (EC 2.3.1.137)protein59148% helix, 15% strandQ9DC50
BPeroxisomal carnitine O-octanoyltransferase (EC 2.3.1.137)protein60048% helix, 15% strandQ9DC50

Ligands and binding sites

  • MPD · (4S)-2-methyl-2,4-pentanediol · additive · 9 copies · chains A, B
  • EPE · 4-(2-hydroxyethyl)-1-piperazine ethanesulfonic acid · additive · 2 copies · chains A, B

Binding sites are the residues within 4.5 Å of a ligand's heavy atoms.

Pockets

8 pockets found on a 1 Å grid, 5 with a druggability of 0.5 or more.

PocketVolume (ų)DruggabilityBuriednessLining residuesInside
18320.790.8269EPE, MPD
28610.780.8173EPE, MPD
3690.630.9116empty
4900.620.8919empty
5880.560.8621empty

Modifications

Observed in the structure: 34 modified (engineered).

Compared structures

  • 1XL7 · Crystal Structure of Mouse Carnitine Octanoyltransferase · the same entry in another collection · chain A against A, TM-score 1.00
  • Q9DC50 · AlphaFold monomer V2.0 prediction for peroxisomal carnitine O-octanoyltransferase (Q9DC50) · a predicted model of the same protein · chain B against A, TM-score 1.00

Analyse

GL1X is a live explorer of the GenesisL1 blockchain. Turn on JavaScript for search, charts and interactive views.